Skip to content

DHA Supplementation and Pregnancy Outcome

Maternal DHA Supplementation and Pregnancy Outcome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02219399
Enrollment
871
Registered
2014-08-18
Start date
2001-01-31
Completion date
2014-01-31
Last updated
2014-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Keywords

Pregnancy, DHA, Gestational Length, Cognitive Development

Brief summary

Supplementation with DHA during pregnancy will increase gestational length and improve cognitive development.

Detailed description

This was a trial of supplementation with DHA during pregnancy to increase gestational length. Subjects were provided with 300 mg, 600 mg or placebo (olive oil) in a randomized design from week 24-26 of pregnancy until delivery. Gestational age, birth weight and birth length data were collected and infants growth at 2 and 4 months and cognitive development at 4 months and 1 year were measured.

Interventions

DIETARY_SUPPLEMENT600 mg DHA

Pregnant women were given 600 mg DHA in the last trimester of pregnancy

DIETARY_SUPPLEMENT300 mg DHA

Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding

DIETARY_SUPPLEMENTPlacebo

Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period

Sponsors

USDA Beltsville Human Nutrition Research Center
CollaboratorFED
Colorado State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* singleton pregnancy * 18 years of age or older

Exclusion criteria

* cervical incompetence * presence of cervical cerclage * placenta previa * intrauterine infection * known substance abuse * multiple fetuses * current pre-eclampsia * preexisting diabetes

Design outcomes

Primary

MeasureTime frameDescription
Gestational Length13 weeksLength of gestation as measured by Last menstrual period method and US
Cognitive Development4 monthsBayley's Scales of Infant Development measured at 4 months of age

Secondary

MeasureTime frameDescription
Infant birth length13 weeksself-explanatory
Infant Growth Velocity2 months to 4 months of ageChange in infant length and weight from 2 to 4 months of age
Infant birth weight13 weeksself-explanatory
Infant head circumference at birth13 weeksself-explanatory

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026